Current restrictions for human cell-based therapies have been related to technological limitations with regards to cellular proliferation capacity, maintenance of differentiated phenotype for primary human cell culture, and transmission of communicable diseases. We have seen that cultured primary fetal cells from one organ donation could possibly meet the exigent and stringent technical aspects for development of therapeutic products. We could develop a master cell bank (MCB) of 50 homogenous ampoules of 4-5 million cells each from one fetal organ donation (skin) in short periods of time compared to other primary cell types. Safety tests were performed at all stages of the cell banking. MCB ampoules could create a working cell bank to be used for clinical or research use. Monolayer culture of fetal skin cells had a life span of 12-17 passages, and independent cultures obtained from the same organ donation were consistent for protein concentration (with 1.4-fold maximal difference between cultures) as well as gene expression of MMP-14, MMP-3, TIMP-3, and VEGF (1.4-, 1.9-, 2.1-, and 1.4-fold maximal difference between cultures, respectively). Cell cultures derived from four independent fetal skin donations were consistent for cell growth, protein concentration, and gene expression of MDK, PTN, TGF-β1, and OPG. As it is the intention that banked primary fetal cells can profit from the potential treatment of hundreds of thousands of patients with only one organ donation, it is imperative to show consistency, tracability, and safety of the process, including donor tissue selection, cell banking, cell testing, and growth of cells in upscaling for the preparation of cell transplantation.
INTRODUCTION
theses, including artificial hips, knees, intervertebral discs, and teeth. However, long-term survival of implants is limited due to mechanical mismatch between Establishment of cell banks is a crucial step in the process of many vaccines, medicinal products, or tissue-the implant and tissue (16, 19, 24) . Within this context, TEP can provide biological sub-engineering products (TEP). The need for TEP is largely increasing as the population ages. Regeneration capacity stitutes to replace, restore, or repair damaged tissue in a wide range of areas (1,2,4,12, 18, 27, 29) . Skin, however, of mammalian tissue gradually disappears from the embryo to adult state, where healing response leads to the is the most active subject of research and clinical application (18) . The design of TEP includes a biologically formation of fibrosed tissue and loss of organ function. One solution has been to replace deficient organs by active substance and a delivery system. Scaffolds provide a three-dimensional support for cell attachment, grafts. Whereas transplantations of kidneys, bone marrow, liver, lungs, and heart are well-established proce-proliferation, and differentiation as well as for new tissue formation. Combination of material, three-dimen-dures, the demand for organ transplantation cannot be fulfilled due to limited availability of graft and immuno-sion architecture, and degradation rates allow the conception of various scaffolds customized to specific compatibility problems. On the other hand, tissues with high mechanical functions have been replaced with pros-applications. Regarding cell-based TEP for skin, the 676 QUINTIN ET AL.
choice of cell type is of primary importance. Cells used no mechanical properties. Human fetal bone cells were shown to have high proliferation and differentiation abil-for TEP need to be readily expanded in vitro and to retain biological activity for restoring and maintaining ity and could be used as a source of cells for TEP for bone (23, 26) . Although application of fetal cells in TEP organ functions. Autologous cells are usually preferred as they avoid rejection and treatment with immunosup-is broad, high levels of safety and consistency in cell banking are common features necessary for their devel-pressive drugs, but these are limited to the patient and the limitations to this technique reside in the in vitro opment in clinics. Hence, in this article we present the criteria for the establishment of a fetal skin cell bank expansion of the cells (7).
Biopsy from severely burned adjacent skin can be of with emphasis on the consistency and safety aspects necessary for preclinical trials. poor quality and/or cannot yield enough cells for in vitro expansion (13). Additionally, these biopsies on the pa-MATERIALS AND METHODS tient create a second surgical wound, which is generally Fetal Skin Tissue painful and slow healing. Allogenic cells (not from the same individual) have been investigated as an alternative For this study, we have acquired four organ donations of fetal skin with written consent from each mother do-source of cells coming from human or animal (xenogeneic) sources. Again, skin is one main area of allogenic nor as approved by the University Hospital Ethics Committee. Organ donations ranged from 13 to 17 weeks of TEP (9,32), but similar to autologous cell transplantations, in vitro expansion and maintenance of a differenti-gestation (FS1, 14 weeks female; FS2, 17 weeks female; FS3, 13 weeks male; FS4, 14 weeks male), and a 1-4-ated state are major limits (18, 34) .
Stem cells have garnered the hopes of scientists be-cm 2 biopsy from the abdominal region was excised. At this stage, observations concerning the tissue received cause they have high self-renewal capacity and can generate multiple cell lineages (29) . They can be isolated were noted (color, size, consistence) and representative samples were taken and examined microscopically to not only from bone marrow but also from many tissues, such as amniotic fluid, brain, skin, heart, kidneys, and confirm that the tissue was acceptable for subsequent expansion of cells. Tissue was also sent for pathological liver. Although widely distributed, stem cells represent only a small fraction of a tissue cell population, which assessment. For each organ donation, a specific record was pre-requires an extensive in vitro expansion step. Another source of stem cells is blastocytes. These embryonic pared in relation to the donor and to the fetal tissue obtained. Relevant details relating to the health of the stem cells (ESC) can be isolated from early-stage embryo and present the advantage of being pluripotent, un-mother who donated the fetal tissue were specifically recorded as part of the record for the original tissue. The like those from adult stem cells, which can differentiate into a restricted number of cell lineages. patient name was not recorded; the patient was given a reference number for traceability following Good Clini-Cultures of stem cells are technically very demanding. Maintenance and expansion of adult stem cells in cal Practice guidelines. The mother donors were tested for infectious diseases (status of the donor for HIV, an undifferentiated state require the addition of many specific growth factors (1), and so far culture of ESC HBV, and HCV) at the time of tissue donation and again 3 months after to ensure negative sero-conversion (Fig. has not been possible without feeder layers (which are usually formed by animal cells), which is in some part 1, donor testing). Testing and antibodies used were as follows: HBsAg-Cobas Core HbsAgII EIA (Hoffmann-responsible for the inconsistent colony cell growth (20) . The necessity to use exogenous growth factors as well La Roche AG); anti-HIV-1/HIV-2 (Hoffmann-La Roche AG); Cobas Core anti-HIV-1/HIV-2 EIA DAGS II as animal products is a limiting factor for the scale-up of stem cell cultures for clinical applications. Unlike (Hoffmann-La Roche AG); anti HCV-Cobas Core anti-HCV EIA (Hoffmann-La Roche AG); AXSym anti-stem cells, fetal cells are differentiated cells with high expansion, regeneration, and low immunogenicity prop-HCV EIA, version 3.0 (Abbott Diagnostika); PCR-HCV-Cobas Amplicor, version 2.0 (Hoffmann-La erties (2,4). They can be isolated from fetal tissues, which follow embryonic stage at 9 weeks of develop-Roche AG); Treponema pallidum: Serodia-TP.PA (Fujirebio, Almedica AG); anti-CMV-Vidas CMV IgG ment.
Biological bandages composed of fetal skin fibro-(BioMérieux SA); ETI-CYTOK-M reverse (Sorin Diagnostics S.r.L); Toxoplasma gondii-Toxo-Screen DA blasts showed convincing results in regenerating skin in wounds and second and third degree burned children (IgG) and Toxo-ISAGA (IgM) (BioMérieux SA). For the tissue, information concerning the age of the (8,17). Development of fetal cell treatments shows promising results in other areas, such as in orthopedics.
fetus, date, time, and place of acquirement were recorded. Types and amounts of tissue received and into In response to injury, bone yields a fibrosis tissue with ANALYSIS OF FETAL SKIN BANKS 677 how many containers were also recorded. The containers Although the donor was obviously a human source, isoenzyme testing to show Caucasian human origin was were then labeled with the identification code before transfer to the laboratory. Details of the medium into necessary for documentation. Other tests were sterility, mycoplasma, and retroviral reverse transcriptase activity which the tissues were collected (DMEM, Gibco), together with supplier, batch number, and certificates were (FPERT assay). Examinations for viruses, virus-like particles, mycoplasmas, fungi, yeasts, and bacteria were attached to the record. Sterility and microbiological testing of the media were performed and specific containers done with a minimum profile of 200 cells with quantitative transmission electron microscopy. In vitro testing of with medium were provided to the medical doctor responsible and kept in a designated refrigerator. Prior to picornovirus, orthomyxovirus, pramyxovirus, herpesvirus, adenovirus, and reovirus was accomplished with transfer to the laboratory, the tissue was stored for less than half a day in the designated refrigerator, under lock several control cell lines. In vivo virus testing was completed using suckling mice, adult mice, guinea pigs, and and key, that was accessed only by the medical doctor. embryonated eggs. Human virus detection was screened Processing of the Fetal Skin Tissue using Q-PCR for all of the following viruses: HepB, HepC, HIV-1, HIV-2, HTLV-1, HTLV-2, HHV-6, Specific cell culture from biopsy material has been previously described elsewhere (8,17) and is repre-HHV-7, HHV-8, EBV, hCMV, SV40. B19 parovirus was also screened with Q-PCR ( Fig. 1 , MCB testing). sented, in part, in Figure 1 . Briefly, fetal skin biopsies were cleaned of adherent tissue, washed three times for All of the extensive tests were accomplished and validated in the GMP facilities of Bioreliance (Glasgow, 15 min each in phosphate-buffered saline (PBS: NaCl 6.80 g/L, Na 2 HPO 4 1.48 g/L, KH 2 PO 4 0.43 g/L), dis-Scotland). Safety testing of the working cell bank (WCB) for preclinical and research projects can then be sected, and put into culture in tissue culture grade plates (60 cm, Falcon). Once the adherent cells reached 80% somewhat limited compared to the MCB safety testing because each MCB ampoule results in a full WCB (Fig. confluence, they were trypsinized (EDTA and trypsin solution, Gibco), amplified, and ampoules of cells in 1 1, WCB testing). Safety testing for laboratory researchdeveloped cell banks need to be continually controlled ml of freezing medium (50% DMEM, 40% FCS, 10% DMSO) were stored in liquid nitrogen. Cell banks were for mycoplasma and bacterial contamination. stored in the vapor phase of alarm-fitted (to assure suffi-Consistency of Processing of Tissue cient liquid nitrogen) liquid nitrogen storage vessels (Carbagas) rather than in the liquid phase, and portions
We derived three MCB and WCB from one initial fetal skin tissue to look at variability of fresh tissue pro-of each cell bank were split between different vessels in separate locations for security.
cessing. The initial fetal skin tissue was divided into three equivalent sections. Each section was treated as an Although very extensive data tracking is essential for GMP records, for our laboratory cell banks we prepared independent tissue according to the procedure described above. Protein concentration and mRNA level of MMP-a certificate of analysis for each cell bank, giving its designation, number of ampoules prepared, date, tests 14, MMP-3, TIMP-3, and VEGF were measured at passage 3 in triplicate in each of the three independent cul-performed, specification, and results. Ampoules were labeled with the cell bank code and each ampoule individ-tures designated as A, B, and C. Protein concentration was measured in fetal cell extract obtained by freeze-ually numbered. Logbooks were used to record all ampoule movements including the initial deposit of the cell thaw cycles with Bradford Protein Assay (Biorad, CA, USA) using albumin from bovine serum fraction V for bank and also each time an ampoule was removed, whether for testing or for experimental purposes. These the standard curve. Total RNA was isolated from cultured cells using the NucleoSpin, RNA II kit (Marchery-changes were signed and dated in the cell bank logbook.
Nagel, Düren, Germany) as described by the manufac-Safety Testing turer. One microgram of total RNA was reverse transcribed using the 50 units of StratScript reverse transcript-The master cell bank (MCB) of one cell line destined for clinical use was characterized and extensively tested ase enzyme (Stratagene, San Diego, CA, USA) in a volume of 50 µl containing 1× first-strand buffer (Strata-in the GMP facilities of Bioreliance in Glascow, Scotland to demonstrate the absence of viruses (Fig. 1, MCB gene), 3 µl of random primers (100 ng/µl) (Promega, Madison, WI, USA), 40 units of RNasin (Promega), and testing). Testing requirements were based on those required for human diploid cells used for vaccine produc-2 µl of dNTP mix 100 mM (Promega) as described by the manufacturer. mRNA expression of matrix metallo-tion (33) and for cell substrates used for biotechnological products (6). All the tests performed are listed in proteinase-3 (MMP-3), MMP-14, tissue inhibitor of metalloproteinase-3 (TIMP-3), vascular endothelial growth Figure 1 . factor, and β-actin were measured by real-time PCR us-ferent concentrations could stimulate aged skin cell growth and with higher concentrations to look at poten-ing TaqMan Gene Expression Assays (Applied Biosytems). Measurements were performed in triplicates. tial toxicity (1-2 × 10 6 cells/extract). Relative gene expressions were analyzed with the 2 −∆∆CT RESULTS method and normalized to β-actin gene.
Cell Banking Life Span of Cell Lines
With our fetal tissue we deviate from a conventional The entire life span of each cell line was determined process of cell banking, which is usually started with an to define limitations of cell bank usage. Cellular life ampoule of frozen cells. Our MCB was not from frozen span was defined as the number of in vitro passages cells, but derived from the fresh fetal tissue itself. A until the growth rate was reduced to 25% of the initial MCB of 50 ampoules of 5 million cells at passage 1 maximum growth rate. Three independent cell cultures could be established from each fetal skin biopsy. Each (A, B, and C) were serially cultured in monolayer from ampoule of cells in the MCB was mixed to assure conpassage 2 to 18. Each week using the previous passage, sistency and that each was identical. Ampoules of cells three new plates with 3,000 or 6,000 cells per cm 2 were from the MCB were then expanded by serial subculture prepared for a total of 18 weeks. Cell number was manuup to passage 2 and pooled for distribution into amally counted after 7 days of culture for each passage.
poules to form the WCB, for which vials were then used Once the cell life had been determined for each fetal for specific research projects or preclinical trials. The skin fibroblast cell line, some cells were retained to pro-WCB generated consisted of 50 ampoules each with 5 vide cells for testing beyond the production limit (exmillion cells in each one for each fetal tissue at passage tended passage). These cells were stored as an "ex-2 and 4, respectively (Fig. 1) . tended-life cell bank" and were tested to confirm that Life Span of Fetal Cell Lines they still possess the same characteristics as those from the WCB with respect to karyology, morphology, iden-Actual cell counts were conducted each week with tity, and biological activity.
two media changes on triplicate plates of cells after 7 days of cell growth for two different initial concentra-Consistency Between Biopsies of Different tions of cells: 3,000 and 6,000 cells/cm 2 . Each week us-Tissue Donations ing the previous passage, three new plates with these We derived master and working cell banks from four concentrations were prepared for a total of 18 weeks. fetal donors (FS1, 14 weeks; FS2, 17 weeks; FS3, 13
For the concentration of 3,000 cells/cm 2 , stable populaweeks; FS4, 14 weeks) to investigate interindividual tions were seen up to passage 12 where cell number variation possibilities at several gestational ages. Protein decreased to 25% of initial cell number. When cells concentration was measured with the Bradford Assay were cultured at 6,000 cells/cm 2 , it was possible to con-(Biorad) in fetal cell extract obtained by freeze-thaw tinue several additional passages to 17 where the growth cycles. The concentration of basic fibroblast growth facwas then reduced to 25% of the growth seen in early tor (bFGF) was measured in fetal cell extract with the passages (Fig. 2) . It is necessary to establish the most human bFGF EIA Kit (Chemicon Internationale, CA, efficient cell life by using the minimum number of ini-USA).
tially seeded cells, which will permit the maximum pro-mRNA expression of Midkine (neurite growth production of a finished product at the passages permitted moting factor 2 NEGF2 or MDK), transforming growth (less than 2/3 the life of the cell line under specific confactor-β1 (TGF-β1), osteoprotegerin (OPG), pleioditions). trophin (PTN), and β-actin were measured by real-time Testing for Clinical and Research Purposes PCR as described above.
All of the tests listed in Figure 1 for MCB testing Biological Activity of Fetal Cell Extracts will need to have a negative result to be cleared for further use. There has to be absolute surety for the absence As an additional consistency test, the biological activity of the cells was tested. Fetal cell extract obtained as of contaminants, whether microbiological or viral, for a product that is destined for clinical use. All passages described above was added to the culture medium of aged adult skin cells (NP/CHFR, male, 76 years old). used for direct application will need to be batch tested with specific criteria fulfilling a batch release record. The number of NP/CHFR skin cells was counted manually in triplicate using a hemocytometer and trypan blue These cell lines will also need to be checked routinely for contamination just before application to the patient. exclusion for viability after 4 days of stimulation with fetal cell extracts (concentrations ranging from 0 to 4 × Regarding research use, testing fetal cells that have been banked in a WCB should have routine testing of myco-10 5 cells/extract) to determine if fetal cell extracts at dif- plasma and microbial contamination conducted every freeze-thaw extract of the three independent cell cultures (A, B, C) at 3,000 cells/cm 2 from passage 1 to 11. month on the cell lines in use (Fig. 1, WCB testing) .
The range of mean protein concentration was 1.7 ± 0.2 Consistency of Tissue Processing µg/µl at passage 0 and 3.9 ± 0.5 µg/µl at passage 5. When looking at the variability between the three inde-From the original fetal tissue, three different cultures were developed and each of these cultures was tested in pendent cultures (A, B, and C), fold difference in protein concentration between A, B, and C was the lowest at triplicate for protein concentration and gene expression ( Fig. 3) . Protein concentration was measured in the passage 0 (1.1-fold difference) and the highest at pas- sage 10 (1.4-fold difference). No significant differences 0.4; FS3: 4.5 ± 0.2 ; FS4: 4.0 ± 0.2 µg/µl) as well as β-FGF concentration, normalized to total protein concen-were noted throughout the cell handling for the same number of cells per extraction. In addition, the three in-tration. mRNA expression of MDK, PTN, TGF-β1, and OPG had a similar level among the four different cell dependent cultures showed relatively consistent mRNA level of genes involved in skin regeneration, MMP-14,
cultures. The maximal fold differences in gene expression between the four cell cultures were 2.2, 2.2, 1.5 and MMP-3, TIMP-3, and VEGF, with maximal fold difference between the three independent cultures of 1.4, 1.9, 3.1, respectively, for MDK, PTN, TGF-β1 and OPG (Fig. 4 ). 2.1 and 1.4, respectively.
Consistency Between Tissues of Different Donors
Biological Activity When added to aged fibroblasts, NP/CHFR, in cell Cell cultures derived from four biopsies from different tissue donations yielded 4.1 (FS1), 4.4 (FS2), 2.9 culture, fetal cell extracts had a stimulatory effect on the cell growth of NP/CHFR cells (Fig. 5 ). The effect was (FS3), and 3.6 (FS4) million cells at passage 4. In addition, protein concentration measured in extracts pro-dose dependent, with a 2.6 increase in growth stimulation of NP/CHFR cells seen with fetal extracts compared cessed by freeze-thawing three times was not different among the four cell cultures (FS1: 4.2 ± 0.7; FS2: 4.6 ± to controls where only buffer was added. At higher doses, the growth stimulation remained at the maximum therapy application for skin TEP. Clinical uses have extended significantly for a wide variety of indications in-height seen. Much higher doses of fetal cell extractfive times what was used in experimentation for growth cluding burns, acute and chronic wounds, skin loss, surgical wounds, and bullous diseases (5, 11, 12, 14, 25, 28) . stimulation (2 × 10 6 cells/extract)-were necessary for some toxicity (20-30%) of target cells and this may This means that stringent controls and testing are necessary to ensure proper safety (6). have also been due, in part, to the increased volume necessary to deliver this dilution of the extract.
For maximum security, it would be best to have extensive testing on cell lines used in preclinical studies.
DISCUSSION
Thus, fetal cells have a major advantage because extensive material for therapeutic usage can be developed Fetal skin cells show qualities required for the establishment of a cell bank to be used for TEP and medicinal from only one organ donation. However, due to the impeding costs, cell banks destined only for research pur-products. The life span and the proliferation rate of the cells allowed to build a MCB of 50 ampoules containing poses are difficult to test thoroughly. Until now, there have been no reported biopharma-4-5 million cells each from only one organ donation. Then each ampoule from the MCB can be derived into ceuticals derived from continuous cell cultures that have been implicated in the transmission of infectious agents a WCB to be used for clinical or research purposes. MCB and WCB have been prepared from fetal skin tis-to humans. Most sources of contamination are adventitious, which means that the contamination is introduced sue in short periods of time compared to other primary cells, which saves not only time but is interesting finan-from an external source such as the medium, trypsin, or serum used in the culture process. Several points of in-cially because GMP sterile facilities are usually rented by the day. Cell banking offers advantages for safe cell terest in cell culture that are to be used in preclinical and clinical trials are that any animal products used in rum production and a guaranteed traceability for each bottle that is destined for cell cultures for preclinical and the cell culture process, such as bovine serum and trypsin, should be virus tested and transmissible spongiform clinical usage. In addition, because of concerns about the transmission of bovine viruses it is recommended encephalopaties (TSE) certified (7). Reported cases of bovine spongiform encephalopathy (BSE) have made it that the serum be inactivated (e.g., by gamma irradiation) prior to use (7). Stringent control of potential viral necessary for stringent testing of serum. As only New Zealand or Australia have no reported BSE, these coun-contamination is particularly important with this product as it is not subject to any purification steps and it is not tries have interesting serum for research and clinical purposes (21) . Other companies (i.e., Hyclone, Gibco) certain what, if any, viral inactivation steps may be applied (7). If EDTA alone can be used for cell detach-assure the contained and well-maintained herds for se- ment, it would be beneficial to avoid the use of trypsin in the development. Cell choice for TEP is of utmost importance, and progress to assure the consistency will because of viral safety concerns or the trypsin will need separate testing. In addition, the use of antibiotics in the be necessary before allowing preclinical trials. Fetal cell research was seriously impeded in the 1980s. Because medium is not an acceptable practice and should also be avoided. Thus, it is necessary to test both of the cell academic programs could not easily continue fundamental research on fetal cells, the means to establish better banks that have been produced but an increased testing should be emphasized on the MCB. primary cell cultures and study consistent processing lost at least a decade of advancement. It was research Once the MCB has been thoroughly screened and shown negative for all of the necessary testing, a less on stem cells that brought cell choice back into the center of study for TEP (3,10, 15, 27, 30, 31 ). Using only one stringent testing platform should be established for the WCB that includes the isoenzyme assay assuring the fetal organ donation, it is possible to develop extensive MCB and WCB. Fetal cells, as already differentiated identity, sterility, and mycoplasma. As extensive viral safety testing was performed on the mother donor when lineage, need low nutritional requirements (i.e., no feeder layers or external growth factors) to establish a tissue was donated and at a 3-month interval to assure there was not sero-conversion; this provides the first se-fully defined consistent cell bank and can easily be assessed for safety, assuring an interesting cell choice for curity for laboratory employees. In vitro testing should be concluded to ensure no adventitious agents were in-TEP. troduced during the preparation of the bank either from
